Brief: NeuroVive Receives FDA Orphan Drug Designation

Abliva AB

18/04/2018 08:18

April 18 (Reuters) - NEUROVIVE PHARMACEUTICAL AB  NVP.ST :
    * NEUROVIVE'S KL1333 RECEIVES FDA ORPHAN DRUG DESIGNATION
FOR
TREATMENT OF MITOCHONDRIAL DISEASES
    * ODD OPENS UP FOR MARKET EXCLUSIVITY FOR SEVEN YEARS WITHIN
US
FOR NEUROVIVE'S KL1333, WHEN AUTHORISED FOR MARKETING

Source text for Eikon:  ID:nWkrb0FqR5 
Further company coverage:  NVP.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))